Free Trial
NASDAQ:NVAX

Novavax (NVAX) Stock Price, News & Analysis

Novavax logo
$9.61
-0.23 (-2.34%)
(As of 10/31/2024 ET)

About Novavax Stock (NASDAQ:NVAX)

Key Stats

Today's Range
$9.51
$9.90
50-Day Range
$9.75
$14.68
52-Week Range
$3.53
$23.86
Volume
3.55 million shs
Average Volume
9.94 million shs
Market Capitalization
$1.54 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.83
Consensus Rating
Hold

Company Overview

Novavax Inc is a biotechnology company that focuses on developing vaccines and biological therapies that combat infectious diseases. The company is headquartered in Gaithersburg, Maryland and has several locations across the United States and Europe. Novavax has a strong track record of developing novel vaccine candidates and has achieved significant milestones in recent years.

In 2020 the company redirected all efforts into finding a vaccine for the COVID-19 pandemic releasing its NVX-CoV2373 vaccine called Nuvaxovid, which has been approved for use in the European Union and Canada. 

Novavax Inc's team is led by CEO John C. Jacobs, who was appointed CEO and board member in Q1 of 2023. Mr. Jacobs has over 25 years of commercial and business operation skills and has demonstrated leadership across multiple therapeutic areas. Mr. Jacobs previously served as CEO and board member at Harmony Biosciences, where he served for five years, leading that company through a successful initial public offering (IPO).

Other notable team members include Dr. Gregory Glenn, the President of Research and Development, with 28 years of vaccine design and regulatory experience. Also noteworthy is Dr. Filip Dubovsky, Novavax Inc's Executive Vice President and Chief Medical Officer, a recognized leader in vaccine development and who joined the company after a 15-year tenure at AstraZeneca, another leading vaccine manufacturer. 

Over the past few years, Novavax has reported steady revenue growth. The company's revenue has increased year over year, reporting net income up each year since 2021. The company's debt levels are high, with total liabilities exceeding total assets for multiple years. Novavax's valuation metrics are in line with industry peers. The company's price-to-earnings ratio and the company's price-to-book ratio are in line with industry peers.

These metrics suggest that the market is valuing Novavax appropriately. Novavax's stock performance has been volatile in recent years. The company's stock price increased significantly in 2020 due to its COVID-19 vaccine development efforts. However, the stock price has since declined, as Novavax has faced delays in obtaining regulatory approvals for its COVID-19 vaccine. Despite these setbacks, the company's long-term prospects remain strong.

The vaccine industry is highly competitive and has significant regulatory and political risks. Novavax faces competition from established pharmaceutical companies, as well as other biotechnology companies that are developing vaccines. However, the company's focus on innovative vaccine candidates, such as its COVID-19 vaccine, gives it a competitive advantage. The vaccine industry is also subject to regulatory risks, as government policy changes can significantly impact the market. Novavax's strong relationships with regulatory agencies give it an advantage in navigating this challenging environment.

Novavax has several growth opportunities in the near term. The company's COVID-19 vaccine has shown promising results in clinical trials and has received regulatory approval in multiple markets. Novavax also has several other vaccine candidates in development, including respiratory syncytial virus (RSV) and influenza vaccines. The company's pipeline of innovative vaccine candidates positions it for long-term growth and success.

Novavax faces several risks and challenges that could impact its long-term success. The company's vaccine candidates are subject to regulatory approval, which can be lengthy and expensive. Novavax also faces significant competition from established pharmaceutical companies and other biotechnology companies. Changes in consumer preferences or shifts in government policies could also impact the market for Novavax's products. 

Novavax Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
71st Percentile Overall Score

NVAX MarketRank™: 

Novavax scored higher than 71% of companies evaluated by MarketBeat, and ranked 333rd out of 997 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Novavax has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 3 buy ratings, 2 hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    Novavax has only been the subject of 3 research reports in the past 90 days.

  • Read more about Novavax's stock forecast and price target.
  • Earnings Growth

    Earnings for Novavax are expected to grow in the coming year, from ($0.90) to ($0.38) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Novavax is -3.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Novavax is -3.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about Novavax's valuation and earnings.
  • Percentage of Shares Shorted

    22.31% of the outstanding shares of Novavax have been sold short.
  • Short Interest Ratio / Days to Cover

    Novavax has a short interest ratio ("days to cover") of 5.3.
  • Change versus previous month

    Short interest in Novavax has recently increased by 5.43%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Novavax does not currently pay a dividend.

  • Dividend Growth

    Novavax does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    22.31% of the outstanding shares of Novavax have been sold short.
  • Short Interest Ratio / Days to Cover

    Novavax has a short interest ratio ("days to cover") of 5.3.
  • Change versus previous month

    Short interest in Novavax has recently increased by 5.43%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Novavax has a news sentiment score of 0.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 8 news articles for Novavax this week, compared to 9 articles on an average week.
  • Search Interest

    Only 41 people have searched for NVAX on MarketBeat in the last 30 days. This is a decrease of -9% compared to the previous 30 days.
  • MarketBeat Follows

    19 people have added Novavax to their MarketBeat watchlist in the last 30 days. This is an increase of 280% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Novavax insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 1.00% of the stock of Novavax is held by insiders.

  • Percentage Held by Institutions

    53.04% of the stock of Novavax is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Novavax's insider trading history.
Receive NVAX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Novavax and its competitors with MarketBeat's FREE daily newsletter.

NVAX Stock News Headlines

Novavax Q3 Earnings A Week Away - Time To Accept A New Reality
The real reason Elon is fully endorsing Trump
Elon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to humanity, there is a war being waged on Elon Musk. This war has nothing to do with X, Elon’s stance on immigration or his support for Donald Trump.
See More Headlines

NVAX Stock Analysis - Frequently Asked Questions

Novavax's stock was trading at $4.80 at the beginning of the year. Since then, NVAX shares have increased by 102.9% and is now trading at $9.74.
View the best growth stocks for 2024 here
.

Novavax, Inc. (NASDAQ:NVAX) released its earnings results on Thursday, August, 8th. The biopharmaceutical company reported $0.99 earnings per share for the quarter, missing the consensus estimate of $1.82 by $0.83. Novavax's revenue for the quarter was down 2.1% compared to the same quarter last year.

Shares of Novavax reverse split on the morning of Friday, May 10th 2019. The 1-20 reverse split was announced on Wednesday, May 8th 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 9th 2019. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Novavax's top institutional shareholders include SG Americas Securities LLC (0.82%), Vontobel Holding Ltd. (0.36%), Creative Planning (0.02%) and China Universal Asset Management Co. Ltd. (0.02%). Insiders that own company stock include James F Young, Filip Dubovsky, Gregory M Glenn and John A Herrmann III.
View institutional ownership trends
.

Shares of NVAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Novavax investors own include NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Moderna (MRNA), Advanced Micro Devices (AMD), Pfizer (PFE) and Alibaba Group (BABA).

Company Calendar

Last Earnings
8/08/2024
Today
10/31/2024
Next Earnings (Estimated)
11/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:NVAX
CUSIP
67000210
Employees
1,543
Year Founded
1987

Price Target and Rating

Average Stock Price Target
$17.83
High Stock Price Target
$26.00
Low Stock Price Target
$9.00
Potential Upside/Downside
+86.5%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
6 Analysts

Profitability

Net Income
$-545,060,000.00
Pretax Margin
-29.25%

Debt

Sales & Book Value

Annual Sales
$983.71 million
Book Value
($6.04) per share

Miscellaneous

Free Float
158,493,000
Market Cap
$1.53 billion
Optionable
Optionable
Beta
2.04

Social Links

(Almost)  Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

This page (NASDAQ:NVAX) was last updated on 10/31/2024 by MarketBeat.com Staff
From Our Partners